Compare Stocks → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALTNYSE:AMTTSE:OSP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$10.18+14.5%$9.90$2.09▼$14.84$477.65M0.084.70 million shs8.49 million shsAMTAmerican Tower$197.59+0.1%$196.21$154.58▼$219.10$92.05B0.682.38 million shs2.17 million shsOSPBrompton Oil SplitC$3.00C$2.48▼C$5.14C$2.86MN/A3,319 shs2,037 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+14.51%+11.75%-26.29%-9.51%+132.95%AMTAmerican Tower+0.10%+1.88%+5.74%-8.47%-0.45%OSPBrompton Oil Split0.00%0.00%-0.66%-10.15%-24.75%Central Banks Preparing for US Dollar Collapse? (Ad)China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune1.3232 of 5 stars3.42.00.00.02.11.70.0AMTAmerican Tower4.6873 of 5 stars2.54.03.33.13.32.51.3OSPBrompton Oil SplitN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune2.75Moderate Buy$15.7554.72% UpsideAMTAmerican Tower2.91Moderate Buy$217.5510.10% UpsideOSPBrompton Oil SplitN/AN/AN/AN/ACurrent Analyst RatingsLatest OSP, ADR, AMT, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/5/2024AMTAmerican TowerBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$224.00 ➝ $234.002/28/2024AMTAmerican TowerBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$235.00 ➝ $228.002/28/2024AMTAmerican TowerJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$236.00 ➝ $230.002/13/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.001/24/2024ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$13.001/24/2024AMTAmerican TowerBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$229.00 ➝ $224.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$430K1,272.03N/AN/A$3.77 per share2.70AMTAmerican Tower$11.14B8.27$9.92 per share19.92$23.30 per share8.48OSPBrompton Oil SplitN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$84.71M-$1.65N/AN/AN/A-20,780.75%-46.99%-42.52%5/9/2024 (Estimated)AMTAmerican Tower$1.48B$3.1862.1418.751.3713.31%12.80%2.24%4/24/2024 (Estimated)OSPBrompton Oil SplitN/A-C$0.40N/AN/AN/AN/AN/AN/AN/ALatest OSP, ADR, AMT, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/27/202412/31/2023AMTAmerican Tower$2.10$0.94-$1.16$0.18$2.74 billion$2.79 billion DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AAMTAmerican Tower$6.803.44%+12.50%213.84%12 YearsOSPBrompton Oil SplitC$1.39N/AN/AN/A N/ALatest OSP, ADR, AMT, and ALT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/14/2024AMTAmerican Towerquarterly$1.623.3%4/11/20244/12/20244/26/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A12.8912.89AMTAmerican Tower3.290.690.69OSPBrompton Oil SplitN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%AMTAmerican Tower92.69%OSPBrompton Oil SplitN/AInsider OwnershipCompanyInsider OwnershipALTAltimmune4.10%AMTAmerican Tower0.24%OSPBrompton Oil SplitN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5253.73 million51.53 millionOptionableAMTAmerican Tower5,643466.35 million465.23 millionOptionableOSPBrompton Oil SplitN/A951,000N/ANot OptionableOSP, ADR, AMT, and ALT HeadlinesSourceHeadlineBrompton Lifeco Split Corp. Pfd.wsj.com - February 18 at 12:51 AMBrompton Split Banc Corp Pref Share SBC.PR.Amorningstar.com - February 8 at 10:46 AMBrompton Split Corp. Preferred Share ETF Announces Increased Distributionsstockhouse.com - February 1 at 2:02 PMBrompton Energy Split Corp (ESP)investing.com - January 6 at 7:22 PMBrompton Oil Split Corp. Announces Name and Ticker Symbol Changemarkets.businessinsider.com - December 18 at 2:31 PMClosing Bell: Brompton Oil Split Corp Pref flat on Thursday (OSP-PR-A)theglobeandmail.com - December 7 at 5:51 PMBrompton Oil Split Corp. Announces Results of Special Meetingfinance.yahoo.com - December 5 at 12:26 PMClosing Bell: Brompton Oil Split Corp Pref up on Thursday (OSP-PR-A)theglobeandmail.com - November 10 at 2:24 PMClosing Bell: Brompton Oil Split Corp down on Friday (OSP)theglobeandmail.com - October 22 at 10:01 AMClosing Bell: Brompton Oil Split Corp flat on Monday (OSP)theglobeandmail.com - October 16 at 8:44 PMClosing Bell: Brompton Oil Split Corp up on Thursday (OSP)theglobeandmail.com - October 12 at 6:35 PMClosing Bell: Brompton Oil Split Corp up on Tuesday (OSP)theglobeandmail.com - October 11 at 9:50 AMBrompton Oil Split Corp Class Amorningstar.com - October 10 at 11:58 PMBrompton Announces Special Meeting of Brompton Oil Split Corp.finance.yahoo.com - October 6 at 3:06 PMClosing Bell: Brompton Oil Split Corp up on Wednesday (OSP)theglobeandmail.com - September 7 at 5:59 AMClosing Bell: Brompton Oil Split Corp Pref up on Friday (OSP-PR-A)theglobeandmail.com - August 12 at 3:24 AMBrompton Lifeco Split Corp. Announces Extension of Termmarkets.businessinsider.com - August 11 at 5:23 PMClosing Bell: Brompton Oil Split Corp up on Friday (OSP)theglobeandmail.com - July 29 at 5:25 PMClosing Bell: Brompton Oil Split Corp flat on Friday (OSP)theglobeandmail.com - July 18 at 8:54 AMClosing Bell: Brompton Oil Split Corp Pref up on Monday (OSP-PR-A)theglobeandmail.com - May 16 at 9:33 AMClosing Bell: Brompton Oil Split Corp Pref down on Thursday (OSP-PR-A)theglobeandmail.com - May 13 at 2:33 PMClosing Bell: Brompton Oil Split Corp Pref down on Friday (OSP-PR-A)theglobeandmail.com - May 6 at 3:00 PMClosing Bell: Brompton Oil Split Corp down on Wednesday (OSP)theglobeandmail.com - May 4 at 7:55 AMClosing Bell: Brompton Oil Split Corp Pref down on Tuesday (OSP-PR-A)theglobeandmail.com - May 3 at 4:53 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways5 Under-the-Radar Artificial Intelligence (AI) Stocks March 4, 2024 9:30 AMView 5 Under-the-Radar Artificial Intelligence (AI) Stocks Intuitive Machines: Charting a Course Among the StarsMarch 21, 2024 11:30 AMView Intuitive Machines: Charting a Course Among the StarsHyatt Hotels Surges on the Leisure and Business Travel Boom March 4, 2024 6:20 AMView Hyatt Hotels Surges on the Leisure and Business Travel Boom Commvault Continues its Rally, Outpacing Tech Stocks, MidcapsMarch 11, 2024 7:00 AMView Commvault Continues its Rally, Outpacing Tech Stocks, MidcapsAll Headlines Company DescriptionsAltimmuneNASDAQ:ALTAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.American TowerNYSE:AMTAmerican Tower, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a portfolio of over 224,000 communications sites and a highly interconnected footprint of U.S. data center facilities.Brompton Oil SplitTSE:OSPBrompton Oil Split Corp. is a closed-ended equity mutual fund launched and managed by Brompton Funds Limited. The fund invests in public equity markets of North America. It primarily invests in dividend paying stocks of large-cap companies having market capitalization of at least $2 billion. The fund invests in stocks of companies which are a constituent of the S&P 500 Index and S&P/TSX Composite Index. It invests in stocks of companies operating in the oil and gas sectors. Brompton Oil Split Corp. was formed on February 24, 2015 and is domiciled in Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.